Day: July 21, 2025

Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses Presentations by expert clinicians and key opinion leaders Company to webcast its R&D Day event today at 11:00 AM Eastern NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host its Frontiers in Brain Health R&D Day today in New York City to review its industry-leading CNS pipeline. The Frontiers in Brain Health R&D Day will feature presentations from the following six leading expert clinicians and key opinion leaders, who will discuss the psychiatric and neurological conditions targeted by the company’s...

Vancouver, B.C., July 21, 2025 (GLOBE NEWSWIRE) — NextGen Digital Platforms Inc. (CSE:NXT) (OTCQB:NXTDF) (FSE:Z12) (“NextGen” or the “Company”) a digital asset and fintech platform focused on bridging traditional capital markets with Web3 infrastructure, is pleased to announce the acquisition of $1.0 million worth of Bitcoin (“BTC”) to be held on its balance sheet as part of its corporate treasury strategy that incorporates the acquisition of certain crypto assets — including Bitcoin, Ethereum, and/or Solana (the “Crypto Assets”). As part of a broader and more diversified approach to managing its corporate reserves, the Company will be allocating a portion of its excess cash into Crypto Assets. These digital assets are being recognized by the Company as potential long-term stores of value and as a hedge against systemic financial...

VANCOUVER, British Columbia, July 21, 2025 (GLOBE NEWSWIRE) — Domestic Metals Corp. (the “Company” or “Domestic”) – (TSXV: DMCU; OTCQB: DMCUF; FSE: 03E) announces that its common shares have started trading on the OTCQB marketplace, a U.S. marketplace operated by OTC Markets Group Inc., as of the opening of markets today. Domestic was previously trading on the OTCID marketplace and will retain its trading symbol of DMCUF on the OTCQB. The Company’s common shares will continue to trade on the TSX Venture Exchange under the symbol DMCU and on the Frankfurt Stock Exchange under the symbol 03E. The OTCQB Venture Market provides an established platform for early-stage and growth companies to enhance their visibility in the U.S. market. Companies listed on OTCQB must meet rigorous reporting standards, undergo annual verification,...

Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP, and existing investors Sessa Capital, the T1D Fund, and ATW Partners Proceeds expected to fully fund completion of pivotal Phase 2b SAFEGUARD study evaluating SAB-142 for delaying progression of autoimmune T1D in newly diagnosed T1D patients (Stage 3) Company expects proceeds to extend cash runway into the middle of 2028 Potential for up to an additional $284 million of gross proceeds if milestone-based warrants exercised in full MIAMI, July 21, 2025 (GLOBE NEWSWIRE) — SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform...

MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced updates to its Retina Scientific Advisory Board (SAB) and Executive Leadership Team to enhance external guidance from key opinion leaders and strengthen the Company’s internal expertise in critical functions and as it pursues its goal of three BLAs in the next three years. “As our novel modifier gene therapy programs continue to progress and demonstrate positive data in the clinic, it is now more important than ever to solidify an optimized Retina SAB reflecting the absolute best guidance in this space as we move closer to commercialization,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “Additionally, it’s imperative...

HIGHLIGHTSUS$450 million project loan facility secured from new strategic partner Appian Capital Advisory to fund the development and construction of the Cariboo Gold Project in B.C., CanadaUS$100 million initial draw enables the Company to accelerate project pre-construction activities and materially de-risk the Project US$350 million in subsequent draws available on a final investment decision subject to certain customary project milestones and conditions precedentStrong endorsement and cornerstone financing commitment from a leading investment fund, exclusively dedicated to long-term value in the mining space Initial draw to support an infill drilling campaign, certain detailed engineering, procurement, underground development, operational readiness planning, and other early works activities Enhances financial flexibility with...

NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in appropriate cancer populations Reflects growing alignment among NCCN, IDSA, and CDC on the role of monoclonal antibodies in protecting immunocompromised individuals from COVID-19 New data published online in JAMA Oncology from the National Cancer Institute COVID-19 in Cancer Patients Study showed COVID-19 had a significant impact on cancer patients, including serious delays or even cessation of cancer treatment and prolonged complicationsWALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), today announced the June 20, 2025 updated National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in...